Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment

Neuroscience Letters

Volumn 391, Issue 1-2, 2005, Pages 48-50

  Buerger, Katharina ^a   Teipel, Stefan J ^a   Zinkowski, Raymond ^b   Sunderland, Trey ^c   Andreasen, Niels ^d   Blennow, Kaj ^e   Ewers, Michael ^a   DeBernardis, John ^b   Shen, Yong ^f   Kerkman, Daniel ^b   Du, Yansheng ^g   Hampel, Harald ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Applied NeuroSolutions Inc   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f SUN HEALTH RESEARCH INSTITUTE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebrospinal fluid; Mild cognitive impairment; Phosphorylated tau protein; Risk factor

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN; THREONINE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGED; APOLIPOPROTEINS E; COGNITION DISORDERS; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; MALE; NERVE TISSUE PROTEINS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS; SWEDEN; TAU PROTEINS; UNITED STATES;

EID: 27844561678     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.08.030     Document Type: Article

References (13)

1. H. Arai, K. Ishiguro, H. Ohno, M. Moriyama, N. Itoh, N. Okamura, T. Mattsui, Y. Morikawa, E. Horikawa, H. Kohno, H. Sasaki, and K. Imahori CSF phosphorylated tau protein and mild cognitive impairment: a prospective study Exp. Neurol. 166 2000 201 203
2. K. Buerger, S.J. Teipel, R. Zinkowski, K. Blennow, H. Arai, R. Engel, K. Hofmann-Kiefer, C. McCulloch, U. Ptok, R. Heun, N. Andreasen, J. DeBernardis, D. Kerkman, H.J. Moeller, P. Davies, and H. Hampel CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects Neurology 59 2002 627 629
3. R.A. Frank, D. Galasko, H. Hampel, J. Hardy, M. De Leon, D.P. Mehta, J. Rogers, E. Siemers, Q.J. Trojanowski, Biological markers for therapeutic trials in Alzheimer's disease, in: Proceedings of the Biological Markers Working Group; NIA Initiative on Neuroimaging in Alzheimer's Disease, National Institute on Aging Biological Markers Working Group, Neurobiol. Aging 24 (2003) 521-536.
4. H. Hampel, K. Buerger, R. Kohnken, S.J. Teipel, R. Zinkowski, H.J. Moeller, S. Rapoport, and P. Davies Tracking of Alzheimer's disease progression with CSF tau protein phosphorylated at threonine 231 Ann. Neurol. 49 2001 545 546
5. H. Hampel, S.J. Teipel, T. Fuchsberger, N. Andreasen, J. Wiltfang, M. Otto, Y. Shen, D. Dodel, Y. Du, M. Farlow, H.J. Möller, K. Blennow, and K. Buerger Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Mol. Psychiatry 9 2004 705 710
6. N. Itoh, H. Arai, K. Urakami, K. Ishiguro, H. Ohno, H. Hampel, K. Buerger, J. Wiltfang, M. Otto, H. Kretzschmar, H.-J. Moeller, M. Imagawa, H. Kohno, K. Nakashima, S. Kuzuhara, H. Sasaki, and K. Imahori Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease Ann. Neurol. 50 2001 150 156
7. R. Kohnken, K. Buerger, R. Zinkowski, C. Miller, D. Kerkman, J. DeBernardis, J. Shen, H.J. Möller, P. Davies, and H. Hampel Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients Neurosci. Lett. 287 2000 187 190
8. R.C. Petersen, G.E. Smith, R.J. Ivnik, E.G. Tangalos, D.J. Schaid, S.N. Thibodeau, E. Kokmen, S.C. Waring, and L.T. Kurland Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals JAMA 26 1995 1274 1278
9. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima, S.N. Thibodeau, and D. Osborne Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N. Engl. J. Med. 334 1996 752 758
10. M. Sjoegren, P. Davidsson, M. Tullberg, L. Minthon, A. Wallin, C. Wikkelso, A.K. Granerus, H. Vanderstichele, E. Vanmechelen, and K. Blennow Both total and phosphorylated tau are increased in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry 70 2001 624 630
11. I. Tesseur, J. Van Dorpe, K. Spittaels, C. Van den Haute, D. Moechars, and F. Van Leuven Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice Am. J. Pathol. 156 2000 951 964
12. U. Thaker, A.M. McDonagh, T. Iwatsubo, C.L. Lendon, S.M. Pickering-Brown, and D. Mann Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease Neuropathol. Appl. Neurobiol. 29 2003 35 44
13. I. Vincent, J.H. Zheng, D.W. Dickson, Y. Kress, and P. Davies Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease Neurobiol. Aging 19 1998 287 296